Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact

Tag: Alzheimer’s dementia

Lilly includes a single primary endpoint of cognition (ADAS-Cog14) to EXPEDITION3 trial
March 15, 2016 Off

Lilly includes a single primary endpoint of cognition (ADAS-Cog14) to EXPEDITION3 trial

By Dino Mustafić

Lilly includes a single primary endpoint of cognition (ADAS-Cog14) to EXPEDITION3 trial

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off
BMS, Bain Capital create new company to focus on therapies for autoimmune diseases

BMS, Bain Capital create new company to focus on therapies for autoimmune diseases

July 29, 2025 0
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine